Sort   by:  
 Page size 
UnknownDenosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Not available
S-EPMC3795889 | biostudies-literature
UnknownCirculating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Not available
S-EPMC5815402 | biostudies-literature
UnknownRadiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Not available
S-EPMC4881370 | biostudies-literature
UnknownPhase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
Not available
S-EPMC4879718 | biostudies-literature
UnknownTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Not available
S-EPMC4872347 | biostudies-literature
Sort   by:  
 Page size